Clinical Trial Update: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (NCT05530421) evaluating selinexor, venetoclax, and dexamethasone (XVenD) in t(11;14)-positive relapsed/refractory multiple myeloma is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Selinexor (selinexor)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Miami | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING